Orexo AB (FRA:C5G) Cyclically Adjusted Revenue per Share: €1.76 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C5G Orexo AB FRA:C5G
41 GF Score
Price €1.32
GF Value €0.32
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Cyclically Adjusted Revenue per Share?

Orexo AB FRA:C5G -1.49% 41 Cyclically Adjusted Revenue per Share is €1.76 as of Jun. 2026. GuruFocus rates FRA:C5G with a GF Score™ of 41/100 and a GF Value™ of €0.32 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orexo AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.008. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.76 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Orexo AB's average Cyclically Adjusted Revenue Growth Rate was -10.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Orexo AB was 10.30% per year. The lowest was -2.80% per year. And the median was 8.00% per year.

As of today (2026-07-25), Orexo AB's current stock price is €1.318. Orexo AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.76. Orexo AB's Cyclically Adjusted PS Ratio of today is 0.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orexo AB was 5.48. The lowest was 0.40. And the median was 1.87.


Orexo AB  (FRA:C5G) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orexo AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.318/1.76
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orexo AB was 5.48. The lowest was 0.40. And the median was 1.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orexo AB Cyclically Adjusted Revenue per Share Related Terms


Orexo AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Orexo AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Cyclically Adjusted Revenue per Share Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 2.01 2.12 1.94 1.86

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.84 1.86 1.79 1.76

FRA:C5G vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orexo AB's Cyclically Adjusted PS Ratio falls into.


FRA:C5G
41GF Score
Orexo AB FRA:C5G
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orexo AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.008/134.1100*134.1100
=0.008

Current CPI (Jun. 2026) = 134.1100.

Orexo AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.549 101.138 0.728
201612 0.550 102.022 0.723
201703 0.387 102.022 0.509
201706 0.472 102.752 0.616
201709 0.502 103.279 0.652
201712 0.555 103.793 0.717
201803 0.397 103.962 0.512
201806 0.561 104.875 0.717
201809 0.591 105.679 0.750
201812 0.634 105.912 0.803
201903 0.471 105.886 0.597
201906 0.523 106.742 0.657
201909 0.611 107.214 0.764
201912 0.641 107.766 0.798
202003 0.455 106.563 0.573
202006 0.492 107.498 0.614
202009 0.415 107.635 0.517
202012 0.468 108.296 0.580
202103 0.380 108.360 0.470
202106 0.411 108.928 0.506
202109 0.418 110.338 0.508
202112 0.408 112.486 0.486
202203 0.442 114.825 0.516
202206 0.405 118.384 0.459
202209 0.434 122.296 0.476
202212 0.413 126.365 0.438
202303 0.412 127.042 0.435
202306 0.393 129.407 0.407
202309 0.384 130.224 0.395
202312 0.431 131.912 0.438
202403 0.357 132.205 0.362
202406 0.395 132.716 0.399
202409 0.348 132.304 0.353
202412 0.021 132.987 0.021
202503 0.035 132.825 0.035
202506 0.011 133.699 0.011
202509 0.265 133.480 0.266
202512 0.009 133.390 0.009
202603 0.012 133.560 0.012
202606 0.008 134.110 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.76 mean?
Orexo AB (FRA:C5G) has a Cyclically Adjusted Revenue per Share of €1.76 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orexo AB and its competitors.
Is Orexo AB's Cyclically Adjusted Revenue per Share too high?
Orexo AB's current Cyclically Adjusted Revenue per Share is €1.76. Overall, Orexo AB has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Orexo AB's Cyclically Adjusted Revenue per Share of €1.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orexo AB and its competitors. Orexo AB's current Cyclically Adjusted Revenue per Share is €1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (FRA:C5G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.32, compared to a current price of €1.32 — trading 311.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.76. Orexo AB's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Orexo AB (FRA:C5G), the current Cyclically Adjusted Revenue per Share is €1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (FRA:C5G) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of €1.32 is trading 311.9% above its estimated GF Value™ of €0.32. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for FRA:C5G:

  • Cyclically Adjusted Revenue per Share: €1.76
  • GF Value™: €0.32 vs. price of €1.32 (311.9% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the FRA:C5G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
41GF Score

Get the complete analysis for FRA:C5G

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.32
Price
€0.32
GF Value